pharmaphorum7d
Regeneron builds in eye disease tech with Oxular takeover
Regeneron has bought Oxular, a UK-based specialist in retinal diseases, in a move that bolsters its already strong position ...
GSK’s GSK’227 receives FDA BTD for treating adults with relapsed osteosarcoma
GSK (GSK) announced that the US Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, for GSK5764227, GSK’227, ...
Seeking Alpha29d
GSK Is Doing The Right Things But Can't Catch A Break - Rating Downgrade
GSK plc's stock downgraded from “Buy” to “Hold” due to litigation risks, disappointing RSV vaccine sales, and competitive pressures in the HIV space. Despite strong cash flow, GSK's Zantac ...
Reuters1mon
GSK's drug combo shown to cut risk of death by 42% in type of blood cancer
Dec 9 (Reuters) - British drugmaker GSK (GSK.L), opens new tab said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the risk of death by 42% in multiple ...
STAT1mon
GSK myeloma medicine improves survival in trial, another step in the drug’s revival
LONDON — A blood cancer treatment from GSK helped patients live longer in a pivotal trial, a significant finding as the once-withdrawn drug mounts a comeback. In the study, a treatment ...
ETF Daily News25d
GSK plc (NYSE:GSK) Receives $43.25 Consensus Target Price from Brokerages
In related news, major shareholder Plc Gsk bought 2,791,930 shares of the company’s stock in a transaction dated Friday, September 27th. The stock was purchased at an average price of $8.00 per ...